Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) Equity Average (2016 - 2025)

Fortress Biotech has reported Equity Average over the past 13 years, most recently at $57.5 million for Q4 2025.

  • Quarterly results put Equity Average at $57.5 million for Q4 2025, up 900.01% from a year ago — trailing twelve months through Dec 2025 was $57.5 million (up 900.01% YoY), and the annual figure for FY2025 was $24.1 million, up 84712.28%.
  • Equity Average for Q4 2025 was $57.5 million at Fortress Biotech, up from $51.3 million in the prior quarter.
  • Over the last five years, Equity Average for FBIO hit a ceiling of $246.3 million in Q2 2021 and a floor of -$14.6 million in Q3 2023.
  • Median Equity Average over the past 5 years was $43.1 million (2025), compared with a mean of $82.1 million.
  • Biggest five-year swings in Equity Average: tumbled 579.81% in 2024 and later surged 1412.43% in 2025.
  • Fortress Biotech's Equity Average stood at $219.2 million in 2021, then plummeted by 65.47% to $75.7 million in 2022, then tumbled by 107.7% to -$5.8 million in 2023, then dropped by 23.39% to -$7.2 million in 2024, then soared by 900.01% to $57.5 million in 2025.
  • The last three reported values for Equity Average were $57.5 million (Q4 2025), $51.3 million (Q3 2025), and $34.9 million (Q2 2025) per Business Quant data.